• Tirzepatide is a once-weekly, prescription injectable for chronic weight management. Originally developed for type 2 diabetes, it targets two incretin receptors – GIP and GLP-1 – to regulate appetite, slow gastric emptying, and stabilize blood sugar. In eligible adults with obesity or those who are overweight with related health risks, this dual action can reduce

  • The recently approved under-the-skin injection represents a groundbreaking advancement in the field of chronic weight management. It is specifically designed for adults struggling with general obesity or overweight conditions. This innovative medication offers a promising solution for individuals seeking effective long-term weight control. Administered through a convenient injection, it targets adipose tissue, aiding in the